Cerevel Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and $33. price target.
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Cerevel Therapeutics with an Overweight rating and a price target of $33. This has led to an increase in the trading of Cerevel Therapeutics shares.
September 28, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cerevel Therapeutics' stock is trading higher following Piper Sandler's initiation of coverage with an Overweight rating and a $33 price target.
The initiation of coverage by a major financial institution like Piper Sandler generally leads to increased investor interest and trading volume. The Overweight rating indicates that Piper Sandler believes the stock will outperform the market, which can lead to a positive sentiment among investors and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100